2023/03/31 by Grace S. Feng, Joanna Kent, Peter J. Fuller +4 · 1 voice
Medicine · #Hormonal Regulation and Hypertension #Adrenal Hormones and Disorders #Adrenal and Paraganglionic Tumors
paper · pdf · doi:10.55563/clinexprheumatol/h58aqe
openalex publication_date 2023/03/31 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/22
Primary aldosteronism (PA) is the most common endocrine cause of secondary hypertension and is associated with a high risk of cardiovascular disease in the general population. Patients suffering from systemic lupus erythematosus (SLE), a multisystem and multifactorial autoimmune disease, experience a high burden of hypertension and cardiovascular disease. Importantly, cardiovascular disease is one of the leading causes of death in SLE. Very limited evidence suggests an increased proportion of autoimmune diseases such as SLE in patients with PA. However, studies evaluating the prevalence of PA in the SLE population are lacking. Despite the potential for curative or targeted treatments, guidelines for the management of hypertension in SLE do not currently recommend testing for PA. This review highlights PA as a potentially over-looked secondary cause of hypertension in SLE, and offers future directions in research to improve the detection of this highly modifiable cardiovascular risk factor in the SLE population.